Correspondence 0001104659-22-124950 from GridAI Technologies Corp. (GRDX)

GridAI Technologies Corp.
Date: Dec. 6, 2022 · CIK: 0001604191 · Accession: 0001104659-22-124950

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-268660

Date

December 6, 2022

Author

James Sapirstein

Form

CORRESP

Company

GridAI Technologies Corp.

Letter

Re:

December 6, 2022

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

First Wave BioPharma, Inc. (the “Company”)

Registration Statement on Form S-3 (File No. 333-268660)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on December 8, 2022, or as soon as practicable thereafter.

Please call Jack Hogoboom of Lowenstein Sandler LLP at (973) 597-2382 to confirm the effectiveness of the Registration Statement or with any questions.

Very truly yours,
FIRST WAVE BIOPHARMA, INC.

Show Raw Text

CORRESP
1
filename1.htm

December 6, 2022

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

    Re:

    First Wave BioPharma, Inc. (the “Company”)

    Registration Statement on Form S-3 (File No.
    333-268660)

Ladies and Gentlemen:

In accordance with Rule 461
under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration
Statement”) be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on December 8, 2022, or
as soon as practicable thereafter.

Please call Jack Hogoboom
of Lowenstein Sandler LLP at (973) 597-2382 to confirm the effectiveness of the Registration Statement or with any questions.

    Very truly yours,

    FIRST WAVE BIOPHARMA, INC.

    By:
    /s/ James Sapirstein

    Name:
    James Sapirstein

    Title:

    President, Chief Executive Officer and Chairman of the Board

    (Principal Executive Officer)

SecProbe.io